Ticrynafen | CAS# 40180-04-9 | diuretic, antihypertensive

MedKoo Cat#: 412482 | Name: Ticrynafen

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ticrynafen is a novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.

Chemical Structure

Ticrynafen

CAS#40180-04-9

Theoretical Analysis

MedKoo Cat#: 412482

Name: Ticrynafen

CAS#: 40180-04-9

Chemical Formula: C13H8Cl2O4S

Exact Mass: 329.9520

Molecular Weight: 331.16

Elemental Analysis: C, 47.15; H, 2.44; Cl, 21.41; O, 19.32; S, 9.68

Price and Availability

Size	Price	Availability
5mg	USD 238.00	2 Weeks
10mg	USD 388.00	2 Weeks
25mg	USD 711.00	2 Weeks
50mg	USD 1,114.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Ticrynafen; ANP3624; ANP-3624; ANP 3624; Tienilic Acid

IUPAC/Chemical Name

2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid

InChi Key

AGHANLSBXUWXTB-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)

SMILES Code

OC(COc1c(Cl)c(Cl)c(C(c2sccc2)=O)cc1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C21M11C06

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 331.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: King AM, Grant I, Rainville PD, Isaac G, Coen M, Wilson ID, Plumb RS. Capillary ultra performance liquid chromatography-tandem mass spectrometry analysis of tienilic acid metabolites in urine following intravenous administration to the rat. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 15;1087-1088:142-148. doi: 10.1016/j.jchromb.2018.04.034. Epub 2018 Apr 26. PMID: 29738964. 2: Murayama N, Yajima K, Hikawa M, Shimura K, Ishii Y, Takada M, Uno Y, Utoh M, Iwasaki K, Yamazaki H. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies. Biopharm Drug Dispos. 2018 Feb;39(2):116-121. doi: 10.1002/bdd.2115. Epub 2017 Dec 21. PMID: 29136681. 3: Verbitskiy EV, Cheprakova EM, Slepukhin PA, Kravchenko MA, Skornyakov SN, Rusinov GL, Chupakhin ON, Charushin VN. Synthesis, and structure-activity relationship for C(4) and/or C(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds. Eur J Med Chem. 2015 Jun 5;97:225-34. doi: 10.1016/j.ejmech.2015.05.007. Epub 2015 May 7. PMID: 25982331. 4: Tay S, Le H, Ford KA, Nelson SD, Khojasteh SC, Rademacher PM. Mechanistic studies of the cationic binding pocket of CYP2C9 in vitro and in silico: metabolism of nonionizable analogs of tienilic acid. Drug Metab Dispos. 2014 Nov;42(11):1955-63. doi: 10.1124/dmd.114.059022. Epub 2014 Sep 3. PMID: 25187484. 5: Gramec D, Peterlin Mašič L, Sollner Dolenc M. Bioactivation potential of thiophene-containing drugs. Chem Res Toxicol. 2014 Aug 18;27(8):1344-58. doi: 10.1021/tx500134g. Epub 2014 Jul 21. PMID: 25014778. 6: Coen M, Rademacher PM, Zou W, Scott M, Ganey PE, Roth R, Nelson SD. Comparative NMR-based metabonomic investigation of the metabolic phenotype associated with tienilic acid and tienilic acid isomer. Chem Res Toxicol. 2012 Nov 19;25(11):2412-22. doi: 10.1021/tx3002803. Epub 2012 Nov 5. PMID: 23013248. 7: Koen YM, Sarma D, Williams TD, Galeva NA, Obach RS, Hanzlik RP. Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes. Chem Res Toxicol. 2012 May 21;25(5):1145-54. doi: 10.1021/tx300103j. Epub 2012 Apr 10. PMID: 22462724; PMCID: PMC3358484. 8: Rademacher PM, Woods CM, Huang Q, Szklarz GD, Nelson SD. Differential oxidation of two thiophene-containing regioisomers to reactive metabolites by cytochrome P450 2C9. Chem Res Toxicol. 2012 Apr 16;25(4):895-903. doi: 10.1021/tx200519d. Epub 2012 Mar 14. PMID: 22329513; PMCID: PMC3339269. 9: Flora DR, Tracy TS. Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism- based inactivator. Drug Metab Dispos. 2012 Apr;40(4):836-42. doi: 10.1124/dmd.111.043372. Epub 2011 Dec 28. PMID: 22205778; PMCID: PMC3310422. 10: Nishiya T, Kato M, Suzuki T, Maru C, Kataoka H, Hattori C, Mori K, Jindo T, Tanaka Y, Manabe S. Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats. Toxicol Lett. 2008 Dec 15;183(1-3):81-9. doi: 10.1016/j.toxlet.2008.10.009. Epub 2008 Nov 1. PMID: 18992796. 11: Hutzler JM, Balogh LM, Zientek M, Kumar V, Tracy TS. Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos. 2009 Jan;37(1):59-65. doi: 10.1124/dmd.108.023358. Epub 2008 Oct 6. PMID: 18838506; PMCID: PMC2610245. 12: Nishiya T, Mori K, Hattori C, Kai K, Kataoka H, Masubuchi N, Jindo T, Manabe S. The crucial protective role of glutathione against tienilic acid hepatotoxicity in rats. Toxicol Appl Pharmacol. 2008 Oct 15;232(2):280-91. doi: 10.1016/j.taap.2008.06.024. Epub 2008 Jul 22. PMID: 18708081. 13: Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. Can in vitro metabolism- dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol. 2008 Sep;21(9):1814-22. doi: 10.1021/tx800161s. Epub 2008 Aug 9. PMID: 18690722. 14: Takakusa H, Masumoto H, Mitsuru A, Okazaki O, Sudo K. Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. Drug Metab Dispos. 2008 May;36(5):816-23. doi: 10.1124/dmd.107.018002. Epub 2008 Jan 28. PMID: 18227147. 15: Shiradkar MR, Padhalingappa MB, Bhetalabhotala S, Akula KC, Tupe DA, Pinninti RR, Thummanagoti S. A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease. Bioorg Med Chem. 2007 Oct 1;15(19):6397-406. doi: 10.1016/j.bmc.2007.06.053. Epub 2007 Jul 4. PMID: 17643991. 16: McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. Evaluation of time- dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos. 2006 Aug;34(8):1291-300. doi: 10.1124/dmd.106.009969. Epub 2006 May 5. PMID: 16679385. 17: Nishiya T, Kataoka H, Mori K, Goto M, Sugawara T, Furuhama K. Tienilic acid enhances hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic multidrug resistance-associated protein 3 and heme oxygenase-1 induction. Toxicol Sci. 2006 Jun;91(2):651-9. doi: 10.1093/toxsci/kfj162. Epub 2006 Mar 16. PMID: 16543292. 18: Rao PV, Shimazaki A, Ichikawa M, Franse-Carman L, Alvarado JA, Epstein DL. Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. Biol Pharm Bull. 2005 Dec;28(12):2189-96. doi: 10.1248/bpb.28.2189. Erratum in: Biol Pharm Bull. 2006 Jun;29(6):1304. Franse-Carman, Linda [added]. PMID: 16327147. 19: López-García MP, Dansette PM, Coloma J. Kinetics of tienilic acid bioactivation and functional generation of drug-protein adducts in intact rat hepatocytes. Biochem Pharmacol. 2005 Dec 5;70(12):1870-82. doi: 10.1016/j.bcp.2005.09.026. Epub 2005 Oct 28. PMID: 16257391. 20: Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, Mansuy D. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys. 2003 Jan 1;409(1):80-91. doi: 10.1016/s0003-9861(02)00548-9. PMID: 12464247.